Ghrelin Amplifies the Nicotine-Induced Release of Dopamine in the Bed Nucleus of Stria Terminalis (BNST).

BSNT dopamine ghrelin nicotine superfusion

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
04 Sep 2023
Historique:
received: 31 07 2023
revised: 02 09 2023
accepted: 03 09 2023
medline: 28 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Ghrelin is an orexigenic neuropeptide that is known for stimulating the release of growth hormone (GH) and appetite. In addition, ghrelin has been implicated in addiction to drugs such as nicotine. Nicotine is the principal psychoactive component in tobacco and is responsible for the reward sensation produced by smoking. In our previous in vitro superfusion studies, it was demonstrated that ghrelin and nicotine stimulate equally the dopamine release in the rat amygdala, and ghrelin amplifies the nicotine-induced dopamine release in the rat striatum. However, less attention was paid to the actions of ghrelin and nicotine in the bed nucleus of the stria terminalis (BNST). Therefore, in the present study, nicotine and ghrelin were superfused to the BNST of male Wistar rats, and the dopamine release from the BNST was measured in vitro. In order to determine which receptors mediate these effects, mecamylamine, a non-selective nicotinic acetylcholine receptor (nAchR) antagonist, and GHRP-6, a selective growth hormone secretagogue receptor (GHS-R1A) antagonist, were also superfused to the rat BNST. Nicotine significantly increased the release of dopamine, and this effect was significantly inhibited by mecamylamine. Ghrelin increased dopamine release even more significantly than nicotine did, and this effect was significantly inhibited by GHRP-6. Moreover, when administered together, ghrelin significantly amplified the nicotine-induced release of dopamine in the BNST, and this additive effect was reversed partly by mecamylamine and partly by GHRP-6. Therefore, the present study provides a new base of evidence for the involvement of ghrelin in dopamine signaling implicated in nicotine addiction.

Identifiants

pubmed: 37760897
pii: biomedicines11092456
doi: 10.3390/biomedicines11092456
pmc: PMC10525377
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Neuropsychopharmacology. 2009 Jan;34(2):266-81
pubmed: 18418357
Nitric Oxide. 2023 Feb 1;131:1-7
pubmed: 36513266
Neuropharmacology. 2006 Oct;51(5):1013-22
pubmed: 16904135
Neuroscience. 2010 Dec 29;171(4):1180-6
pubmed: 20933579
Neuropsychopharmacol Rep. 2022 Jun;42(2):233-237
pubmed: 35437943
Curr Opin Pharmacol. 2005 Feb;5(1):53-9
pubmed: 15661626
Nicotine Tob Res. 2004 Dec;6(6):899-912
pubmed: 15801566
Alcohol Clin Exp Res. 2018 May 24;:
pubmed: 29797564
Eur Neuropsychopharmacol. 2008 Jul;18(7):508-18
pubmed: 18343642
Addict Biol. 2006 Mar;11(1):45-54
pubmed: 16759336
Brain Res. 1985 Dec 2;348(2):355-8
pubmed: 4075093
Biol Psychol. 2018 Jan;131:14-30
pubmed: 28011402
Addict Biol. 2007 Mar;12(1):6-16
pubmed: 17407492
J Neurochem. 1997 Apr;68(4):1511-9
pubmed: 9084421
Gastroenterology. 2001 Feb;120(2):337-45
pubmed: 11159873
Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):169-73
pubmed: 3185744
Neurochem Res. 2013 Oct;38(10):1989-95
pubmed: 23836294
Synapse. 2003 Apr;48(1):45-56
pubmed: 12557272
Nature. 1999 Dec 9;402(6762):656-60
pubmed: 10604470
Brain Res Bull. 2022 Oct 1;188:179-186
pubmed: 35901985
Br J Pharmacol Chemother. 1953 Sep;8(3):321-6
pubmed: 13093953
Learn Mem. 2004 Jan-Feb;11(1):60-9
pubmed: 14747518
J Comp Neurol. 2002 Dec 2;454(1):15-33
pubmed: 12410615
Peptides. 2005 Nov;26(11):2274-9
pubmed: 16137788
Mol Psychiatry. 2016 Apr;21(4):450-63
pubmed: 26878891
Cell. 2011 Sep 16;146(6):992-1003
pubmed: 21925320
Int Rev Neurobiol. 2017;136:89-119
pubmed: 29056157
J Neural Transm (Vienna). 2018 Dec;125(12):1885-1889
pubmed: 30251224
J Neurosci. 1996 Jan 15;16(2):714-22
pubmed: 8551354
Brain Res. 2019 Mar 1;1706:41-47
pubmed: 30722977
Biol Psychiatry. 2013 Jul 1;74(1):69-76
pubmed: 23260335
Alcohol Clin Exp Res. 2022 Dec;46(12):2149-2159
pubmed: 36316764
Psychoneuroendocrinology. 2014 Nov;49:253-9
pubmed: 25127083
Life Sci. 1979 Oct 1;25(14):1257-62
pubmed: 513957
Physiol Behav. 2019 May 15;204:49-57
pubmed: 30738971
Front Neuroendocrinol. 2010 Jan;31(1):104-12
pubmed: 19836414
Psychopharmacology (Berl). 2014 Jul;231(14):2725-40
pubmed: 24947976
Neurochem Int. 2013 Oct;63(4):239-43
pubmed: 23831084
Curr Neuropharmacol. 2009 Mar;7(1):37-49
pubmed: 19721816
Gen Pharmacol. 1991;22(1):117-9
pubmed: 2050279
J Neuropsychiatry Clin Neurosci. 2003 Summer;15(3):306-16
pubmed: 12928506
Addict Behav. 2021 Jul;118:106866
pubmed: 33640833
Addict Biol. 2012 Mar;17(2):452-64
pubmed: 21392177
Brain Res. 1987 May;434(2):117-65
pubmed: 3107759
Behav Brain Res. 2021 Aug 6;411:113401
pubmed: 34090941
Ann Nutr Metab. 2018;73(1):54-61
pubmed: 29940599
Neurosci Biobehav Rev. 2004 Jan;27(8):713-20
pubmed: 15019421
Neuroscience. 2000;96(4):735-42
pubmed: 10727791
Neurosci Lett. 2006 May 29;400(1-2):140-5
pubmed: 16563623
Neurosci Lett. 2006 Nov 27;409(1):47-51
pubmed: 17010518
J Pharmacol Exp Ther. 1997 Mar;280(3):1432-44
pubmed: 9067333
Brain Res. 2016 Dec 1;1652:21-29
pubmed: 27693397
Horm Behav. 2006 Aug;50(2):266-73
pubmed: 16643913
Neuropharmacology. 2023 Nov 1;238:109643
pubmed: 37369277
Nicotine Tob Res. 2000 Feb;2(1):19-37
pubmed: 11072438
Neuropsychopharmacology. 2013 Jan;38(2):364-75
pubmed: 22968812
J Neurosci. 2006 Apr 5;26(14):3855-63
pubmed: 16597740
Physiol Behav. 2011 Mar 28;102(5):481-4
pubmed: 21163280
Neurochem Res. 1995 Jun;20(6):753-9
pubmed: 7566373
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11318-23
pubmed: 19564604
Biol Psychol. 2018 Jan;131:43-48
pubmed: 28300626
PLoS One. 2012;7(11):e49557
pubmed: 23166710
J Neurosci. 2019 May 22;39(21):4009-4022
pubmed: 30782976
Eur J Histochem. 2014 Jul 18;58(3):2400
pubmed: 25308843
Eur Neuropsychopharmacol. 2016 Sep;26(9):1378-1389
pubmed: 27461514
Neuropharmacology. 2000;39(1):88-98
pubmed: 10665822
Pharmacol Biochem Behav. 2018 Sep;172:39-49
pubmed: 30030128
Drug News Perspect. 2010 Apr;23(3):157-66
pubmed: 20440417
Neuropharmacology. 2017 Aug 1;122:100-106
pubmed: 28351600
Behav Brain Res. 2011 Aug 1;221(1):182-8
pubmed: 21392542
Ann Nutr Metab. 2015;66(2-3):155-161
pubmed: 25896493
Int J Endocrinol. 2014;2014:575671
pubmed: 24808912
Neurochem Res. 2005 Aug;30(8):1055-66
pubmed: 16258855
Addict Biol. 2022 Jan;27(1):e13033
pubmed: 33908131
Pharmacol Biochem Behav. 2022 Jul;218:173423
pubmed: 35750154
Mol Cell Endocrinol. 2004 Feb 12;214(1-2):81-95
pubmed: 15062547
J Neurosci. 2000 Oct 15;20(20):RC102
pubmed: 11027253
Biol Psychiatry. 2012 Feb 15;71(4):327-34
pubmed: 22115620
World J Biol Psychiatry. 2020 Dec;21(10):748-756
pubmed: 31552785
Neurosci Biobehav Rev. 2007;31(3):287-314
pubmed: 17141870
Pharm Acta Helv. 2000 Mar;74(2-3):103-14
pubmed: 10812946
Addict Biol. 2021 Jan;26(1):e12864
pubmed: 31849152
J Neurosci. 2007 Aug 1;27(31):8161-5
pubmed: 17670959
Brain Res Mol Brain Res. 1997 Aug;48(1):23-9
pubmed: 9379845

Auteurs

Jázmin Ayman (J)

Department of Obstetrics and Gynecology, Albert Szent-Györgyi School of Medicine, University of Szeged, H-6701 Szeged, Hungary.

Miklós Palotai (M)

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Roberta Dochnal (R)

Department of Pediatrics and Pediatric Health Center, Albert Szent-Györgyi School of Medicine, University of Szeged, H-6701 Szeged, Hungary.

Zsolt Bagosi (Z)

Department of Pathophysiology, Albert Szent-Györgyi School of Medicine, University of Szeged, H-6725 Szeged, Hungary.

Classifications MeSH